Introduction
The ECTRIMS Newsletter is a quarterly release of news and information related to ECTRIMS and its activities. It is sent by email to all ECTRIMS-interested parties. Subscribe here.
Newsletter
Newsletter
Current issue: December 2021
Wrapping up ECTRIMS 2021; Updated Vaccination Standards for People with Multiple Sclerosis; Updated DMT Guidelines.
New Insights Revealed at ECTRIMS 2021
And that’s a wrap! The 37th Annual Congress of ECTRIMS, held 13–15 October under a fully digital landscape, strived to connect our community with the latest news in cutting edge science from leading experts from around the world for the benefit of people affected by MS.
The programme combined scheduled Scientific Sessions, Hot Topics and Meet the Experts with live Q&A discussions and on-demand content including 967 ePosters.
This year, our sessions and streams were divided into four main topics to help you find the session most suitable for you (Clinical, Pathogenesis, Imaging and Non-Imaging Biomarkers/Translational, and Global Views).
We also introduced special streams for the Educational and Nurse Sessions, Speaker Interviews, and Daily Highlights to give participants an executive summary of the main takeaways of each day.
As a registered delegate you have exclusive access to the digital congress platform, session recordings via on demand videos and scientific content like ePosters, until 5 January 2022. Registration is open during this period
Make sure to mark your calendar: ECTRIMS 2022 will be held in Amsterdam on 26-28 October. Details will follow at a later date, but we are already brainstorming to work out a possible new hybrid format, which will enable both onsite and digital participation.
EAN/ECTRIMS Consensus Report on Vaccination in MS Patients
Do vaccines increase the risk of MS? Do they increase the risk of relapses or disability progression? Are they effective when using disease modifying treatments?
The therapeutic arsenal for MS has grown considerably in recent years and, in this context, vaccination has become an important part of the risk management strategy in MS patients. Naturally, many questions have arisen over how vaccinations affect MS patients, and how they should best manage their vaccination plans.
Against this backdrop, ECTRIMS and EAN joined forces over the last year to develop a European, evidence-based consensus report on vaccination in people with MS. The consensus report, which will be published at a later date, includes 59 recommendations and covers the following topics:
- Safety and immunogenicity of vaccinations in MS – current evidence
- Effectiveness (in terms of immunogenicity) of vaccines in patients with and without immunosuppressive therapy
- Vaccination strategy in MS patients before, during and after immunosuppressive therapy
- Vaccination strategies in special groups (ie those who are pregnancy, children, elderly or travelling internationally)
This joint initiative was presented at the Annual Congress on 15 October in the ECTRIMS-EAN Session: “Therapy and Global Views”. Visit the ECTRIMS Congress website to watch the full presentation.
Additional newsletter topics
- Updated Clinical Guideline of the Pharmacological Treatment of People with Multiple Sclerosis to be Released Early Next Year
- ECTRIMS Fellowship Report – MS Clinical Training Fellowship Awardee 2019
- Update Your ECTRIMS Subscription Preferences